Opendata, web and dolomites

ThyroTrust

A novel reliable diagnostic device to avoid unnecessary thyroid surgery

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ThyroTrust project word cloud

Explore the words cloud of the ThyroTrust project. It provides you a very rough idea of what is the project "ThyroTrust" about.

effect    ipr    proposing    generation    malignant    italy    manufacturing    performed    panel    types    financial    adverse    66    fine    cytology    cancer    scope    lesion    measured    genes    diagnostic    route    abolishment    needle    thyrotrust    outcome    aspiration    740    plan    either    rearrangements    classified    planning    benign    life    44000    26    million    fna    histology       thyroidectomy    market    postoperative    addressable    price    cos    indeterminate    introduce    first    clinically    variations    opportunity    innovation    replacement    cytological    strategy    reveal    estimation    kit    diagnostics    15    300    surgery    ivd    forcing    business    surgeries    unnecessary    nodules    sequencing    ce    90    positive    patients    procedure    complications    prevalence    ing    negative    tool    80    diagnosis    hormone    thyroid    expression    fnac    time    surgical    social    virtually    feasibility    influences    47    quality    considerable    search    correct    gene    lt    clinical    frequent    category    risk    malignancy    30    idea    organization    validated    prudentially   

Project "ThyroTrust" data sheet

The following table provides information about the project.

Coordinator
GENOMNIA SRL 

Organization address
address: CORSO MAGENTA 56
city: MILANO
postcode: 20123
website: www.genomnia.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.genomnia.it
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2016-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GENOMNIA SRL IT (MILANO) coordinator 50˙000.00

Map

 Project objective

Fine needle aspiration cytology (FNAC) is the best procedure for a timely and reliable diagnosis of either a benign or malignant thyroid lesion. However, the management of patients with indeterminate cytology (10-26%) is a frequent clinical and social problem, as this cytological category is associated with a 15 to 30% prevalence of malignancy, forcing most of these patients to diagnostic surgery. However, for the 80% of these patients the surgery is unnecessary as the postoperative histology reveal a benign lesion. The negative social and financial consequences of this approach are relevant in Europe (44000/year thyroidectomy only in Italy) as well as the adverse influences on the quality of life of the patients due to surgical complications and hormone replacement. We will introduce in the market the first clinically validated CE-IVD targeted Next Generation Sequencing diagnostic kit ThyroTrust for the correct diagnosis of thyroid nodules with indeterminate cytology. Our kit is the first to include a considerable number of variations in 47 genes, 66 types of rearrangements and 8 gene expression level measured at the same time and associated with malignant outcome. This will avoid diagnostic surgery if a risk of malignancy <5%. In the scope of the feasibility study we will assess: - Technology innovation opportunity and business idea - Development planning and partner search - IPR, quality, organization and manufacturing route - GO-TO-MARKET strategy and business plan 740,000 FNA are performed in Europe, so the addressable market, with an end-user price/kit of 300€, is over €50 Million/year. Prudentially, market estimation considers only FNA results classified as “indeterminate cytology”. The same approach could be evaluated and adopted for other cancer diagnostics, proposing a similar gene panel kit on the market. The positive effect resulting from such diagnostic tool can virtually lead to the abolishment of 90% of unnecessary surgeries and related cos

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THYROTRUST" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THYROTRUST" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More